Search - tctmd.com

Displaying 241 - 260 of 307

Sort: Relevancy | Date

News Conference News HFSA 2019

Old Dog, New Tricks? HOMAGE Hints at Role for Spironolactone in HF Prevention

L.A. McKeown

September 24, 2019

News Conference News HFSA 2019

DEFINE-HF: Dapagliflozin Improves Function and QoL, but Not Biomarkers, in HFrEF

L.A. McKeown

September 16, 2019

News Conference News ESC 2019

DAPA-HF Details: Dapagliflozin Slashes HF Outcomes, Even in Nondiabetics

Shelley Wood

September 01, 2019

News Daily News

Young Survivors of Childhood Cancer Have Higher, Earlier Risk of CVD Events

L.A. McKeown

August 30, 2019

News Conference News ESC 2019

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

Shelley Wood

August 22, 2019

News Daily News

DAPA-HF: Dapagliflozin Scores a Win in Heart Failure

Todd Neale

August 20, 2019

News Daily News

CV Risk Factors in Youth May Prove Indelible for Later CAD

Marcus A. Banks

July 17, 2019

News Industry News

U.S. FDA Grants Fast Track Designation to Empagliflozin for the Treatment of Chronic Heart Failure

June 26, 2019

News Industry News

Health Library: Hypertension (High Blood Pressure)

June 24, 2019

News Conference News ESC Heart Failure 2019

Steep Rise in PCI for Ischemic Heart Failure Seen in Sweden, but Survival Favors CABG

Shelley Wood

May 28, 2019

News Conference News ESC Heart Failure 2019

Weaning Off Diuretics in Stable Heart Failure? ReBIC-1 Hints at Possibilities

Shelley Wood

May 28, 2019

News Daily News

Elevations in hs-cTnI Linked to Higher Risk of CVD, Particularly Heart Failure

Michael O'Riordan

May 06, 2019

News Daily News

Mortality From Heart Failure Increasing in United States

Michael O'Riordan

May 06, 2019

News Daily News

Younger Type 2 Diabetes Patients Face Higher Mortality and CVD Risks

Michael O'Riordan

April 10, 2019

News Conference News ACC 2019

New DECLARE-TIMI 58 Data Shine a Light on Diabetes Patients Most Likely to Benefit From Dapagliflozin

Shelley Wood

March 26, 2019

News Daily News

Sex-Based Differences for Heart Failure Risk Need More Attention, Research

Yael L. Maxwell

February 28, 2019

News Daily News

How HF Drugs Help and Harm Female Patients: A Call for Sex-Specific Reporting

Shelley Wood

February 26, 2019

News Daily News

One in Two Americans Have Cardiovascular Disease: AHA Stats

Michael O'Riordan

February 04, 2019

News Features

Top News in Heart Failure: 2018

Shelley Wood

December 28, 2018

News Conference News AHA 2018

EMPA-HEART Offers Mechanistic Clues for Empagliflozin’s Cardiac Benefits

Michael O'Riordan

November 16, 2018

Advertisement

Old Dog, New Tricks? HOMAGE Hints at Role for Spironolactone in HF Prevention

DEFINE-HF: Dapagliflozin Improves Function and QoL, but Not Biomarkers, in HFrEF

DAPA-HF Details: Dapagliflozin Slashes HF Outcomes, Even in Nondiabetics

Young Survivors of Childhood Cancer Have Higher, Earlier Risk of CVD Events

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

DAPA-HF: Dapagliflozin Scores a Win in Heart Failure

CV Risk Factors in Youth May Prove Indelible for Later CAD

U.S. FDA Grants Fast Track Designation to Empagliflozin for the Treatment of Chronic Heart Failure

Health Library: Hypertension (High Blood Pressure)

Steep Rise in PCI for Ischemic Heart Failure Seen in Sweden, but Survival Favors CABG

Weaning Off Diuretics in Stable Heart Failure? ReBIC-1 Hints at Possibilities

Elevations in hs-cTnI Linked to Higher Risk of CVD, Particularly Heart Failure

Mortality From Heart Failure Increasing in United States

Younger Type 2 Diabetes Patients Face Higher Mortality and CVD Risks

New DECLARE-TIMI 58 Data Shine a Light on Diabetes Patients Most Likely to Benefit From Dapagliflozin

Sex-Based Differences for Heart Failure Risk Need More Attention, Research

How HF Drugs Help and Harm Female Patients: A Call for Sex-Specific Reporting

One in Two Americans Have Cardiovascular Disease: AHA Stats

Top News in Heart Failure: 2018

EMPA-HEART Offers Mechanistic Clues for Empagliflozin’s Cardiac Benefits

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content